These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 27770778)
1. Observational study on patterns of neuromuscular blockade reversal. Dubovoy T; Housey M; Devine S; Kheterpal S BMC Anesthesiol; 2016 Oct; 16(1):103. PubMed ID: 27770778 [TBL] [Abstract][Full Text] [Related]
3. [Influence of neostigmine on the course of neuromuscular blockade with rocuronium or cisatracurium: a randomized, double-blind trial]. Barrio J; San Miguel G; García V; Pelegrín F Rev Esp Anestesiol Reanim; 2007; 54(7):399-404. PubMed ID: 17953333 [TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study. Saager L; Maiese EM; Bash LD; Meyer TA; Minkowitz H; Groudine S; Philip BK; Tanaka P; Gan TJ; Rodriguez-Blanco Y; Soto R; Heisel O J Clin Anesth; 2019 Aug; 55():33-41. PubMed ID: 30594097 [TBL] [Abstract][Full Text] [Related]
5. The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade. Fortier LP; McKeen D; Turner K; de Médicis É; Warriner B; Jones PM; Chaput A; Pouliot JF; Galarneau A Anesth Analg; 2015 Aug; 121(2):366-72. PubMed ID: 25902322 [TBL] [Abstract][Full Text] [Related]
6. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Sacan O; White PF; Tufanogullari B; Klein K Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210 [TBL] [Abstract][Full Text] [Related]
7. Antagonism of atracurium-induced block in obese patients. Kirkegaard-Nielsen H; Lindholm P; Petersen HS; Severinsen IK Can J Anaesth; 1998 Jan; 45(1):39-41. PubMed ID: 9466025 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. Carron M; Zarantonello F; Tellaroli P; Ori C J Clin Anesth; 2016 Dec; 35():1-12. PubMed ID: 27871504 [TBL] [Abstract][Full Text] [Related]
9. Cisatracurium- and rocuronium-associated residual neuromuscular dysfunction under intraoperative neuromuscular monitoring and postoperative neostigmine reversal: a single-blind randomized trial. Feltracco P; Tonetti T; Barbieri S; Frigo AC; Ori C J Clin Anesth; 2016 Dec; 35():198-204. PubMed ID: 27871520 [TBL] [Abstract][Full Text] [Related]
10. Effects of calcium chloride coadministered with neostigmine on neuromuscular blockade recovery: A double-blind randomised study. Ju JW; Kim HC; Yoon S; Hong DM; Park HP Eur J Anaesthesiol; 2017 Sep; 34(9):617-622. PubMed ID: 28763316 [TBL] [Abstract][Full Text] [Related]
11. Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine. Fuchs-Buder T; Meistelman C; Alla F; Grandjean A; Wuthrich Y; Donati F Anesthesiology; 2010 Jan; 112(1):34-40. PubMed ID: 19952724 [TBL] [Abstract][Full Text] [Related]
12. Optimum dose of neostigmine to reverse shallow neuromuscular blockade with rocuronium and cisatracurium. Choi ES; Oh AY; Seo KS; Hwang JW; Ryu JH; Koo BW; Kim BG Anaesthesia; 2016 Apr; 71(4):443-9. PubMed ID: 26874258 [TBL] [Abstract][Full Text] [Related]
13. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265 [TBL] [Abstract][Full Text] [Related]
14. Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults. Abdulatif M; Mowafi H; al-Ghamdi A; el-Sanabary M Br J Anaesth; 1996 Dec; 77(6):710-5. PubMed ID: 9014620 [TBL] [Abstract][Full Text] [Related]
15. Conditions to optimise the reversal action of neostigmine upon a vecuronium-induced neuromuscular block. Baurain MJ; Dernovoi BS; D'Hollander AA; Hennart DA; Cantraine FR Acta Anaesthesiol Scand; 1996 May; 40(5):574-8. PubMed ID: 8792887 [TBL] [Abstract][Full Text] [Related]
16. Low-dose neostigmine to antagonise shallow atracurium neuromuscular block during inhalational anaesthesia: A randomised controlled trial. Fuchs-Buder T; Baumann C; De Guis J; Guerci P; Meistelman C Eur J Anaesthesiol; 2013 Oct; 30(10):594-8. PubMed ID: 23803594 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic doses of neostigmine, depolarising neuromuscular blockade and muscle weakness in awake volunteers: a double-blind, placebo-controlled, randomised volunteer study. Kent NB; Liang SS; Phillips S; Smith NA; Khandkar C; Eikermann M; Stewart PA Anaesthesia; 2018 Sep; 73(9):1079-1089. PubMed ID: 30132821 [TBL] [Abstract][Full Text] [Related]
18. Use of sugammadex after neostigmine incomplete reversal of rocuronium-induced neuromuscular blockade. de Menezes CC; Peceguini LA; Silva ED; Simões CM Rev Bras Anestesiol; 2012 Jul; 62(4):543-7. PubMed ID: 22793970 [TBL] [Abstract][Full Text] [Related]
19. Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade. Kirkegaard-Nielsen H; Helbo-Hansen HS; Lindholm P; Severinsen IK; Pedersen HS; Jensen EW Can J Anaesth; 1996 Sep; 43(9):932-8. PubMed ID: 8874911 [TBL] [Abstract][Full Text] [Related]
20. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. Suzuki T; Masaki G; Ogawa S Br J Anaesth; 2006 Aug; 97(2):160-3. PubMed ID: 16782976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]